Trial Profile
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AMG 319 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 08 Feb 2017 Status changed from active, no longer recruiting to completed.
- 15 Jan 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 17 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.